FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Biblioteca de Peptídeos

PT-141

Bremelanotide / Vyleesi

Sexual Health

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II, developed specifically to isolate the sexual function effects from the tanning properties of its parent compound. It was FDA-approved in 2019 under the brand name Vyleesi for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the few peptides to achieve full regulatory approval. PT-141 works centrally through melanocortin-4 receptor (MC4R) activation in the hypothalamus rather than through vascular mechanisms like PDE5 inhibitors.

Mecanismo de Ação

Melanocortin-4 receptor (MC4R) agonist derived from Melanotan II. Acts centrally in the hypothalamus to increase sexual desire and arousal through dopaminergic pathways. Unlike PDE5 inhibitors, works on desire rather than mechanical erectile function.

Protocolos de Pesquisa

Para fins de pesquisa apenas. Não é conselhos médicos.

Research protocols use 1-2mg via subcutaneous injection 45 minutes before anticipated activity. Maximum frequency: once per 24 hours, no more than 8 times per month. FDA-approved dose for HSDD is 1.75mg.

Notas de Pesquisa

Clinical Research Status

PT-141 received FDA approval in June 2019 as Vyleesi (bremelanotide) for HSDD in premenopausal women, administered as a 1.75mg subcutaneous auto-injector used as-needed before sexual activity. Phase 3 RECONNECT trials demonstrated statistically significant improvements in sexual desire and reduction in distress compared to placebo. Research continues into male erectile dysfunction applications, where it has shown efficacy in patients who do not respond to PDE5 inhibitors.

Key Published Findings

Clinical trials showed that PT-141 increased the number of satisfying sexual events and improved desire scores in women with HSDD over 24-week treatment periods. In male ED studies, it produced erections in men unresponsive to sildenafil, confirming its unique central mechanism of action. Functional MRI studies demonstrate that PT-141 activates brain regions associated with sexual arousal, distinguishing it mechanistically from all other sexual dysfunction treatments.

Safety Profile

The most common side effect is nausea, occurring in approximately 40% of patients and typically diminishing with repeated use. Flushing, headache, and transient hypertension are reported in 10-20% of users. The FDA label carries a warning about transient blood pressure increases and recommends against use in patients with uncontrolled hypertension or cardiovascular disease. Dosing is limited to no more than once every 24 hours and no more than 8 doses per month.

Drug Interactions & Contraindications

PT-141 may cause additive hypotension when combined with naltrexone or other opioid antagonists used for HSDD treatment. Not recommended for use with other melanocortin receptor agonists due to overlapping receptor activity. Contraindicated in uncontrolled hypertension and should be used cautiously with antihypertensive medications due to unpredictable blood pressure effects.

Comparison to Related Compounds

Unlike PDE5 inhibitors (sildenafil, tadalafil) which work peripherally on vascular smooth muscle, PT-141 acts centrally on sexual desire and arousal pathways in the brain. Derived from Melanotan II but engineered to minimize melanocortin-1 receptor activity (tanning) while preserving MC4R activity (sexual function). It is the only FDA-approved treatment that directly targets the neurological component of sexual desire rather than the mechanical vascular response.

Community Observations

Research dosing for males typically ranges from 500mcg to 2mg subcutaneously, administered 2-4 hours before anticipated sexual activity. Nausea management is the primary challenge, with many users reporting that starting at lower doses (250-500mcg) and titrating up reduces initial GI side effects. Effects typically onset within 1-3 hours and can persist for 6-12 hours, with some users reporting residual effects lasting up to 72 hours.

Meio-Vivo

~2-3 hours

Reconstituição

Bacteriostatic water (BAC)

Armazenamento

Liofilizado

Refrigerate 2-8C up to 24 months.

Reconstituído

Refrigerate 2-8C. Use within 30 days.

Situação Legal nos EUA

FDA-approved for HSDD in women (Rx only)

Também Conhecido Como

BremelanotideVyleesi

Perguntas frequentes

O que é PT-141?

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist derived from Melanotan II, developed specifically to isolate the sexual function effects from the tanning properties of its parent compound. It was FDA-approved in 2019 under the brand name Vyleesi for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the few peptides to achieve full regulatory approval. PT-141 works centrally through melanocortin-4 receptor (MC4R) activation in the hypothalamus rather than through vascular mechanisms like PDE5 inhibitors.

Como PT-141 funciona?

Melanocortin-4 receptor (MC4R) agonist derived from Melanotan II. Acts centrally in the hypothalamus to increase sexual desire and arousal through dopaminergic pathways. Unlike PDE5 inhibitors, works on desire rather than mechanical erectile function.

Qual é o status regulatório de PT-141 nos EUA?

FDA-approved for HSDD in women (Rx only)

Qual é a meia-vida de PT-141?

~2-3 hours

Por quais outros nomes PT-141 é conhecido?

Bremelanotide, Vyleesi

Peptide Contacts fornece resumos baseados em pesquisas apenas para fins informativos. Não hospedamos, distribuímos ou endossamos documentação de fornecedores. Todas as certificações de análise completa, certificados GMP e comunicações de fornecedores devem ser solicitadas e verificadas diretamente pelo comprador. Nada nesta plataforma constitui conselhos legais, médicos ou profissionais. Os usuários são unicamente responsáveis por verificar as credenciais dos fornecedores e garantir a conformidade com todas as leis locais, estaduais e federais aplicáveis antes de adquirir qualquer química de pesquisa. O uso desta plataforma constitui aceitação plena da responsabilidade pessoal.

Leia a declaração completa